{"id":5699,"date":"2024-04-29T10:13:35","date_gmt":"2024-04-29T15:13:35","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5699"},"modified":"2025-06-27T11:19:04","modified_gmt":"2025-06-27T16:19:04","slug":"nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/","title":{"rendered":"Nanoscope Therapeutics se presentar\u00e1 en las cumbres de innovaci\u00f3n en terapia g\u00e9nica y celular de la retina y OIS"},"content":{"rendered":"
\n
\n
\n

<\/h1>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span><\/span>, 29 de abril de 2024<\/span><\/span>\u00a0 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en fase avanzada que desarrolla terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy que Samarendra Mohanty<\/span>, PhD, cofundador y presidente, presentar\u00e1 en el Cumbre de innovaci\u00f3n en terapia g\u00e9nica y c\u00e9lulas de la retina 2024<\/a> y el Cumbre de innovaci\u00f3n de retina de la fuente de innovaci\u00f3n en oftalmolog\u00eda (OIS)<\/a>, ambos en Seattle, Washington<\/span>. El equipo directivo estar\u00e1 presente en estos eventos. Los detalles de las presentaciones son los siguientes:<\/p>\n

Cumbre de innovaci\u00f3n en terapia gen\u00e9tica y c\u00e9lulas de la retina de la Fundaci\u00f3n que Lucha contra la Ceguera 2024<\/a>
T\u00edtulo de presentaci\u00f3n: <\/b>Navegando los desaf\u00edos regulatorios para avanzar en las terapias g\u00e9nicas
T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Dise\u00f1o de ensayos cl\u00ednicos: regulatorio
Fecha de la sesi\u00f3n:<\/b>\u00a03 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b>\u00a04:55 \u2013 5:10 p.m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Hyatt Regency Seattle
Presentador<\/b>: Samarendra Mohanty, PhD, cofundadora y presidenta<\/p>\n

En su presentaci\u00f3n, el Dr. Mohanty presentar\u00e1 los desaf\u00edos regulatorios cl\u00ednicos y de fabricaci\u00f3n para avanzar en las terapias gen\u00e9ticas para las enfermedades de la retina. Compartir\u00e1 las lecciones aprendidas al trabajar con las autoridades reguladoras en el dise\u00f1o y desarrollo de ensayos para medir la potencia de los productos de terapia g\u00e9nica y los criterios de valoraci\u00f3n de eficacia en los ensayos cl\u00ednicos.<\/p>\n

Cumbre de innovaci\u00f3n de retina de la fuente de innovaci\u00f3n en oftalmolog\u00eda (OIS)<\/a>
T\u00edtulo de presentaci\u00f3n: <\/b>Restauraci\u00f3n de la visi\u00f3n independiente de mutaciones en pacientes con degeneraci\u00f3n de retina
T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Enfoque en la medicina regenerativa
Fecha de la sesi\u00f3n:<\/b>\u00a04 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b> 3:00 \u2013 4:05 p.m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Hotel Four Seasons Seattle
Presentador<\/b>: Samarendra Mohanty, PhD, cofundadora y presidenta<\/p>\n

El Dr. Mohanty ofrecer\u00e1 una actualizaci\u00f3n corporativa sobre las pr\u00f3ximas actividades de Nanoscope tras los datos preliminares positivos del ensayo cl\u00ednico aleatorizado de Opsina Multicaracter\u00edstica (MCO) en retinosis pigmentaria (RP). A continuaci\u00f3n, tendr\u00e1 lugar una mesa redonda sobre medicina regenerativa moderada por Mark S. Humayun, MD, PhD, profesor de Oftalmolog\u00eda y codirector.Universidad del Sur de California<\/span> Instituto Roski del Ojo.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas gen\u00e9ticamente independientes que restauran la vista para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El principal activo de la empresa, MCO-010, datos recientemente anunciados de 100 semanas de<\/a> la fase de RESTAURACI\u00d3N 2b<\/span>\/3 ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para RP (NCT04945772). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con enfermedad de Stargardt (NCT05417126). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la RP como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para atrofias geogr\u00e1ficas secundarias a la degeneraci\u00f3n macular relacionada con la edad.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS, April 29, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Samarendra Mohanty, PhD, Co-Founder, and President, will present in the Retinal Cell and Gene Therapy Innovation Summit 2024 and the Ophthalmology Innovation Source\u00a0(OIS) Retina Innovation Summit, both taking place in\u00a0Seattle, Washington. The […]<\/p>\n","protected":false},"author":6,"featured_media":5703,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5699","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-29T15:13:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:19:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits\",\"datePublished\":\"2024-04-29T15:13:35+00:00\",\"dateModified\":\"2025-06-27T16:19:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/\"},\"wordCount\":397,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/\",\"name\":\"Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg\",\"datePublished\":\"2024-04-29T15:13:35+00:00\",\"dateModified\":\"2025-06-27T16:19:04+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/29\\\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus productos en las Cumbres de Innovaci\u00f3n en Terapia Celular y G\u00e9nica de la OIS y la Retinal - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-04-29T15:13:35+00:00","article_modified_time":"2025-06-27T16:19:04+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits","datePublished":"2024-04-29T15:13:35+00:00","dateModified":"2025-06-27T16:19:04+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/"},"wordCount":397,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/","url":"https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/","name":"Nanoscope Therapeutics presentar\u00e1 sus productos en las Cumbres de Innovaci\u00f3n en Terapia Celular y G\u00e9nica de la OIS y la Retinal - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg","datePublished":"2024-04-29T15:13:35+00:00","dateModified":"2025-06-27T16:19:04+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_OIS-FFB_2024_REV3.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/29\/nanoscope-therapeutics-to-present-at-the-ois-and-retinal-cell-and-gene-therapy-innovation-summits\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5699"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5699\/revisions"}],"predecessor-version":[{"id":9048,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5699\/revisions\/9048"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5703"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}